3. With the gradual relaxation of the US Biosafety Law on innovative drugs on our side, the recent pharmaceutical sector has obviously picked up, which has promoted a rebound to varying degrees. However, before the fundamentals improve, it is really not easy to really strengthen.
3. With the gradual relaxation of the US Biosafety Law on innovative drugs on our side, the recent pharmaceutical sector has obviously picked up, which has promoted a rebound to varying degrees. However, before the fundamentals improve, it is really not easy to really strengthen.
3. With the gradual relaxation of the US Biosafety Law on innovative drugs on our side, the recent pharmaceutical sector has obviously picked up, which has promoted a rebound to varying degrees. However, before the fundamentals improve, it is really not easy to really strengthen.3. With the gradual relaxation of the US Biosafety Law on innovative drugs on our side, the recent pharmaceutical sector has obviously picked up, which has promoted a rebound to varying degrees. However, before the fundamentals improve, it is really not easy to really strengthen.